Mesa Laboratories, Inc. Declares Quarterly Dividend of $0.16 per Share

Mesa Laboratories declared a quarterly dividend of $0.16 per share, payable March 17, 2025.

Quiver AI Summary

Mesa Laboratories, Inc. announced a quarterly dividend of $0.16 per share, payable on March 17, 2025, to shareholders recorded by February 28, 2025. The company is recognized for its leadership in providing life science tools and quality control solutions in regulated industries such as pharmaceuticals and healthcare. The release also includes a caution about forward-looking statements, highlighting potential risks and uncertainties that could impact future results, urging readers to be aware of these risks and not to overly rely on such statements. For more details about the company, interested parties are directed to visit its website.

Potential Positives

• The declaration of a regular quarterly dividend of $0.16 per share demonstrates Mesa Laboratories' commitment to returning value to shareholders.
• The scheduled payment date for the dividend on March 17, 2025, indicates a stable financial position and confidence in future earnings.
• Being a global leader in life science tools and quality control solutions positions the company favorably in a growing industry, likely attracting investor interest.

Potential Negatives

• Declaring a relatively modest quarterly dividend of $0.16 per share may signal limited cash flow or profit margins, raising concerns among investors about the company's financial health.
• The emphasis on forward-looking statements and the caution regarding risks and uncertainties may contribute to a lack of investor confidence, as it suggests potential instability in future performance.
• The need to reference external documents for further understanding of risks may indicate a lack of transparency in the current press release, potentially leading to mistrust among stakeholders.

FAQ

What is the amount of the declared dividend by Mesa Laboratories?

Mesa Laboratories has declared a quarterly dividend of $0.16 per share of common stock.

When will the dividend be paid to shareholders?

The dividend will be payable on March 17, 2025, to shareholders of record on February 28, 2025.

What industries does Mesa Laboratories serve?

Mesa Laboratories serves the pharmaceutical, healthcare, and medical device industries with life science tools and quality control solutions.

Where can I find more information about Mesa Laboratories?

For more information about Mesa Laboratories, visit their official website at www.mesalabs.com.

What types of statements does this press release include?

This press release includes forward-looking statements that may involve risks and uncertainties affecting future business results.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$MLAB Insider Trading Activity

$MLAB insiders have traded $MLAB stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $MLAB stock by insiders over the last 6 months:

• GARY M OWENS (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 5,069 shares.
• BRIAN DAVID ARCHBOLD (SVP Operations) sold 1,499 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$MLAB Hedge Fund Activity

We have seen 74 institutional investors add shares of $MLAB stock to their portfolio, and 69 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• ROYCE & ASSOCIATES LP removed 47,356 shares (-12.0%) from their portfolio in Q3 2024
• CONESTOGA CAPITAL ADVISORS, LLC removed 43,505 shares (-7.6%) from their portfolio in Q3 2024
• JANUS HENDERSON GROUP PLC removed 35,825 shares (-31.4%) from their portfolio in Q3 2024
• BLACKROCK, INC. added 33,325 shares (+4.1%) to their portfolio in Q3 2024
• FRED ALGER MANAGEMENT, LLC removed 20,570 shares (-100.0%) from their portfolio in Q3 2024
• JANE STREET GROUP, LLC removed 20,134 shares (-89.7%) from their portfolio in Q3 2024
• STATE STREET CORP added 18,128 shares (+9.2%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

Full Release

LAKEWOOD, Colo., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.

Forward Looking Statements

This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections.  Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2024, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.

For more information about the Company, please visit its website at

www.mesalabs.com

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.